This symposium aims to highlight the recent advances and applications of label-free high-throughput cell-based and affinity-selection mass spectrometry (MS) screening assay technologies as an emerging lead discovery strategy. The symposium will bring together leading academic and industry experts to reflect on the opportunities and challenges to exploit state-of-the-art MS-based screening methods to accelerate the discovery of novel starting points for drug discovery.
Dr. Sandra Schulz, CeMOS, Mannheim University of Applied Sciences
Cell-based MALDI MS assays for the characterization of enzymatic reactions and transporter uptake
High throughput capable MALDI-TOF MS has become an emerging analytical technology in drug discovery in recent years. Apart from being label-free, this technique is cost effective and represents a robust read-out for several biochemical assays in industrial settings.
Cell-based MALDI MS assays are still underrepresented as they are more complex and difficult to automate and validate. However, they offer the rare possibility of analysing molecular reactions directly in the cellular context without the necessity of elaborate and time consuming separation methods for cellular components. In this talk, approaches and considerations for the development of MALDI MS cell assays in drug discovery are shown. Moreover, three example assays are presented to underline their strength: the profiling of epigenetic histone deacetylase inhibitors, a mechanistic cell-based assay that monitors inhibition of the fatty acid synthase directly in whole cells using the enzyme specific metabolite malonyl-CoA as FASN reaction readout and a compound screen for the identification of inhibitors of the uptake of estrone-3-sulfate through the transport protein OATP2B1.
Prof. Dr. Carsten Hopf, CeMOS, Mannheim University of Applied Sciences
Perspectives of MALDI MS cell assays – from phenotypic screening to miniaturized assays on droplet microarrays
Mechanistic MALDI MS-based cell assays, which measure single analytes in a cellular context, are successfully transitioning into industry. This talk will introduce participants to phenotypic MALDI MS cell. These acquire information on entire molecular signatures comprising arguably hundreds of molecules simultaneously. These can be analyzed using computational tools to reveal drug-response markers or responses biologically relevant stimuli. In addition, this talk will introduce to MALDI MS cell assays on droplet microarrays that utilize MALDI imaging MS as a readout.
With Carsten Hopf
Head, Center for Mass Spectrometry and Optical Spectroscopy (CeMOS)
Spokesperson M2Aind, Partnership for Innovation in Health Industry
Associated Prof. Medical Faculty, Heidelberg University
The Center for Mass Spectrometry and Optical Spectroscopy (CeMOS) co-creates integrated solutions (devices, chemicals, applications and information technology) with a network of >100 SMEs, with leading academics and with many (inter)nationally well-known companies in biomedicine, IT and beyond. Among other assets, CeMOS operates the Rhine-Neckar-Center for Mass spectrometry imaging and assays and a Leica Imaging reference center for joint projects with industry and academia. CeMOS also orchestrates the partnership for innovation “Multimodal Analytics for the Health Industry” (M2Aind) to promote innovative research and industry transfer in digital technology for (bio)pharma, #chemical, and food #production and to further develop a multimodal platform for drug discovery research.